Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-29 22:30 |
Valneva actualise ses prévisions de revenus pour 2023
|
French | 149.1 KB | ||
| 2023-12-29 22:30 |
Valneva Provides Updated 2023 Financial Guidance
|
English | 150.0 KB | ||
| 2023-12-20 17:45 |
Valneva annonce l’approbation des résolutions présentées à son Assemblée Généra…
|
French | 146.9 KB | ||
| 2023-12-20 17:45 |
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Boar…
|
English | 111.5 KB | ||
| 2023-12-04 22:20 |
Pfizer et Valneva finalisent le recrutement pour l’étude de Phase 3 VALOR sur l…
|
French | 213.6 KB | ||
| 2023-12-04 22:20 |
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Diseas…
|
English | 209.4 KB | ||
| 2023-12-04 07:00 |
Valneva annonce des données positives sur la persistance des anticorps à 24 moi…
|
French | 215.5 KB | ||
| 2023-12-04 07:00 |
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot…
|
English | 179.9 KB | ||
| 2023-11-27 07:00 |
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application f…
|
English | 224.8 KB | ||
| 2023-11-27 07:00 |
L’EMA juge recevable le dossier de demande d’autorisation de mise sur le marché…
|
French | 232.6 KB | ||
| 2023-11-23 10:33 |
Franchissement de seuil
|
French | 268.0 KB | ||
| 2023-11-15 07:30 |
Valneva Announces the Availability of Documentation for its Extraordinary Gener…
|
English | 180.2 KB | ||
| 2023-11-15 07:30 |
Valneva annonce la mise à disposition des documents préparatoires à son Assembl…
|
French | 150.1 KB | ||
| 2023-11-13 07:00 |
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for…
|
English | 180.8 KB | ||
| 2023-11-13 07:00 |
Valneva annonce des résultats positifs de Phase 3 concernant l’immunogénicité d…
|
French | 246.3 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
